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Improving care at home for people with dementia is a core policy goal in the dementia strategies of many European
countries. A challenge to effective home support is the occurrence of crises in the care of people with dementia which arise
from changes in their health and social circumstances. Improving the management of these crises may prevent hospital
admissions and facilitate better and longer care at home. This trial is part of a National Institute for Health Research funded
programme, AQUEDUCT, which aims to improve the quality and effectiveness of teams working to manage crises in
dementia.
METHODS/DESIGN
It is a pragmatic randomised controlled trial of an online Resource Kit to enhance practice in teams managing crises in
dementia care. Thirty teams managing mental health crises in dementia in community settings will be randomised between
the Resource Kit intervention and treatment as usual. The primary outcome measure is psychiatric admissions to hospital for
people with dementia in the teams’ catchment area recorded six months after randomisation. Other outcomes include: quality
of life measures for people with dementia and their carers; practitioner impact measures; acute hospital admissions; and
costs. To enhance understanding of the resource kit intervention, qualitative work will explore staff, patient and carers’
experience.
DISCUSSION
The Resource Kit intervention re ects current policy to enable home-based care for people with dementia by addressing the
management of crises which threaten the viability of care at home. It is based upon a model of best practice for managing
crises in dementia designed to enhance the quality of care, developed in partnership with people with dementia, carers and
practitioners. If the Resource Kit is shown to be clinically and cost effective in this study, this will enhance the probability of
its incorporation into mainstream practice.
TRIAL REGISTRATION: ISRCTN 42855694; Registered on 04/03/2021; Protocol number: 127686/2020v9; Research Ethics
Committee, 09/03/2021, Ref 21/WM/0004; IRAS ID: 289982
https://doi.org/10.1186/ISRCTN42855694
Introduction
Worldwide around 47 million people live with dementia1 including an estimated 850,000 people in the UK.2 Services for
people with dementia in the UK cost over £17 billion a year, even with savings of around £6 billion a year due to the
contribution of family caregivers. In future decades, with an ageing population, increasing numbers of people with dementia
are likely to live at home. As in many countries, improving dementia care is a key priority in England,3,4  with home-oriented
care a key objective of the National Dementia Strategy.5 However,  uctuations in the health and social circumstances of the
person with dementia and their family carers may lead to crisis, breakdown in home care and admissions to hospital or long-
term care. Focused approaches to manage these problems may sustain care at home, improve quality of life and reduce
costs.
Indeed, in one study, one in ten respondents reported a relative with dementia admitted to hospital unnecessarily due to lack
of access to community support.2 For the working age population with mental health problems, Crisis Resolution Teams,
designed to avoid inappropriate hospital admission, have shown some reduction in hospital admissions and improvements
in patient and caregiver satisfaction,6,7,8,9,10 although requiring better de ned service models (Wheeler et al, 2015).11 In
contrast, people with dementia and their carers experiencing crisis are often supported through a variety of different services
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varying in nomenclature, staff mix and operational procedure.12 These services include Community Mental Health Teams,
Crisis Resolution and Home Treatment Teams and generic older people’s rapid response teams. All these services are
described in this paper as Teams Managing Crises in Dementia (TMCDs). Unlike services for younger adults, there appears to
be less evidence and no guidance as to how such teams, or crisis resolution services for older people including those with
dementia, should be designed or operate.13,14
People with dementia, caregivers, and practitioners appear to value a more coordinated approach to crisis management
which is responsive to the unique features of each crisis.15 Home Treatment Packages have been used to help teams
manage crises for people with dementia and their family carers16, with specialist older people’s crisis services identi ed as
providing valuable expertise17,18.  A systematic review and a scoping exercise of crisis interventions in dementia found some
evidence that specialist crisis teams effectively managed crises and reduced hospital admissions, although a more clearly
de ned model of best practice was needed.19  This suggested that crisis intervention approaches could reduce admissions to
psychiatric hospitals for people with dementia, but that stronger evidence to support their e cacy was required and this
informed the development of the AQUEDUCT research programme. 
AQUEDUCT is a National Institute for Health Research (NIHR) funded programme (RP-PG-0612-20004) designed to develop
and evaluate a coherent model of crisis management in dementia care, reducing service variation and enhancing quality and
effectiveness.  Earlier parts of the programme involved a scoping review of the effectiveness of crisis interventions and a
survey of crisis teams which con rmed some evidence of impact upon hospital admissions but with marked variations
across services in England in the pathways to manage crises. It recommended a trial of a standardised care pathway and
measurable intervention to provide better evidence.12   Work with people with dementia, carers and practitioners in mental
health services was undertaken using qualitative methods to develop a model of best practice and associated information
and training materials for TMCDs.14.20 This model underpins a Resource Kit, developed in the AQUEDUCT programme,
designed to provide guidance on best practice and achieve high quality care.  
The AQUEDUCT Trial aims to evaluate the Resource Kit in practice by conducting a randomised controlled trial with a
representative sample of TMCDs across England, examining the impact upon hospital admissions, costs, and upon people
with dementia, carers and staff compared with treatment as usual (TAU).  A Consolidated Standards of Reporting Trials
(CONSORT)  owchart of the trial is shown in Figure 1.
Method/design
The ‘Standard Protocol Items: Recommendation for Interventional Trials’ (SPIRIT) reporting guidelines have been used21 - see
the completed SPIRIT checklist (Additional  le 1).
Governance
Several groups have been established to oversee the trial.  The Programme Management Group (PMG) oversees the full
AQUEDUCT programme of research.  It meets every six months and comprises the Chief Investigator (CI), all collaborators,
researchers, and patient and public involvement (PPI) representatives.  A Trial Steering Group (TSG) has met during set-up
and thereafter at least annually. The TSG membership, approved by the funder, includes an independent Chair, at least two
independent members with appropriate methodological and clinical expertise, one or two PPI representatives (a person with
dementia or carer), the CI and other relevant members of the Trial Management Group (see below). Representatives from
NIHR and from the trial sponsor (Nottinghamshire Healthcare NHS Foundation Trust) may also attend TSG meetings as
active members. The role of the TSG is to: advise the CI on all aspects of the trial; provide overall supervision of the trial
protocol, case report form, and statistical analysis; monitor trial progress; review relevant information from other sources
related to the trial; review outputs and  nal reports; and if necessary, prematurely close the trial.  The programme also has a
standing PPI Reference Group that meets six monthly and is consulted regarding study development. 
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A Trial Management Group (TMG) has met monthly during the set-up of the trial and will then meet monthly or bimonthly, as
appropriate and is accountable to the TSG for trial implementation and operation. It consists of key individuals directly
involved in the development and delivery of the trial including the: CI; Trial Manager; collaborators; and experts by experience.
The role of the TMG is to: monitor trial progress, ensure compliance with and adherence to the project plan; identify and
resolve concerns regarding the intervention and research, including publication authorship; and consider and act on
recommendations of the TSG and Research Ethics Committee. 
A Data Monitoring Committee (DMC), independent of the sponsor and trial, will meet on at least two to three occasions and
consists of a Chair, a statistician, and a clinical researcher. Membership of the DMC has been approved by the funding body.
The role of the DMC is to: review the trial protocol and study materials regarding data management and analysis pertinent to
their duties as the DMC; advise the TSG when it believes the trial protocol should be altered; and advise the TSG if the
committee feels the trial should be prematurely closed.22
The protocol for this present work package was developed in consultation with a Clinical Staff Reference Group, consisting of
National Health Service (NHS) practitioners currently working in TMCDs across England, and the PPI Reference Group.   All
study documentation and participant recruitment procedures have been reviewed by patient and public involvement
representatives.
Design
This is a pragmatic randomised controlled trial of an online Resource Kit for use by TMCDs. It is a two arm, parallel-group,
TAU controlled trial with treatment allocation of teams on a 1:1 ratio. The study aims to randomise 30 teams managing
mental health crises in dementia in community settings between the Resource Kit intervention and treatment as usual. The
null hypothesis is that there is no difference in the effect of crisis care management between teams using the Resource Kit
and TAU. The primary outcome measure is admissions to psychiatric hospitals of people with dementia in the teams’
catchment area, assessed over a six-month period after randomisation.
A feasibility study was conducted for the trial of this Resource Kit, including qualitative work to further shape the intervention
by taking account of participant experiences and preferences.23 This demonstrated that the Resource Kit was acceptable to
and usable by practitioners working in TMCDs, who consistently reported that it accurately re ected their clinical practice.
The feasibility study also identi ed certain di culties experienced by people with dementia and their carers participating
directly in research concerning their TMCD during a personal crisis. Building on these  ndings, iterative consultation with both
the PPI Reference Group and the Clinical Staff Reference Group re ned the trial of the Resource Kit in Crisis Management
addressing both the content of the intervention itself and reducing the demands on participants and the scale of data
collection processes. Implementation is designed to be mindful of pressures on the NHS and research feasibility due to the
COVID-19 pandemic. 
Intervention
The Resource Kit intervention is an online and COVID-19 appropriate resource for TMCDs consisting of two components.  The
 rst is a Fidelity Measure which enables TMCDs to evaluate their practice according to 50 Best Practice Statements in
relation to: the crisis service; rapid assessment and intervention; and service resources. The second, is a Best Practice Toolkit,
consisting of resources for teams to develop speci c aspects of their practice.  The Resource Kit is available as a password-
protected online resource. The research team will provide initial training on completion of the Fidelity Measure and use of the
Best Practice Toolkit.  Each TMCD in the intervention arm will complete the Fidelity Measure before the intervention phase, to
determine areas where practice could be improved. The TMCD will then implement at least four relevant templates from the
Best Practice Toolkit, during the implementation phase of six months. The Fidelity Measure will be repeated at the end of the
intervention phase (after six months). Further details about the intervention are provided in Figure 2.
Treatment as usual
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TMCDs in the control arm will not have access to the Resource Kit, will not complete the Fidelity Measure, and will not use
elements of the Best Practice Toolkit during the six-month implementation phase of the trial, but will continue to conduct
TAU. Both intervention group and TAU group are otherwise free to undertake all usual interventions.
Adherence
Adherence to the overall study protocol by teams in both arms of the study will be supported through weekly contact with the
research team throughout the study.  Following training in the use of the Resource Kit, practitioners in the intervention arm
will complete a self-administered assessment to inform the research team of their level of understanding of the intervention.
Subsequent adherence to the intervention will be adjudged based upon use of the Resource Kit by TMCDs in the intervention
arm.  Speci cally, adherence constitutes: the application and reporting of a Fidelity Measure score at both baseline and
follow up time points; uptake and ongoing utilisation of at least four templates from the Best Practice Toolkit; and
participation in weekly contact with the research team for the study duration.
Setting
The study will take place in NHS Trusts across England which provide mental health services to older people and aims to
recruit 30 TMCDs.  To be eligible, participating Trusts must provide mental health crisis services for older people and must
con rm that they can report all psychiatric hospital admissions, for people with dementia, and provide precise details of local
acute NHS Trust(s) which admit people with dementia from the TMCD’s geographical catchment area, as de ned by
postcode. All NHS Trusts must also con rm, in advance of trial commencement, that the Resource Kit can be used by TMCDs
during the intervention, regardless of the trial arm (intervention or control) to which the team is subsequently allocated.
Participants
Inclusion criteria
Participating teams must be managing dementia mental health crises, de ned as providing urgent mental health assessment
and intervention for people with dementia in the community.  Participants will be staff members of the TMCDs and new
referrals of people with dementia and their carers supported by these teams. 
Exclusion criteria 
To avoid contamination between intervention and control groups, teams will be excluded if they share: immediate
management; administrative or core clinical staff; or the same o ce as another team in the study.  Teams in services
undergoing a major service reorganisation during the study period or in the near future will also be excluded. If a team leader




NHS Trust sites will be recruited via professional and research networks across England, derived from earlier stages of the
research programme.    Participating Trusts will identify teams for inclusion in the study. Purposive recruitment will seek a
diverse range of team service models and service user demographics, re ecting the earlier survey work undertaken in the
study (Streater et al., 2017). Each Trust shall con rm their capacity to undertake the trial by completing the Health Research
Authority Statement of Activities, constituting a formal agreement with the study sponsor.
TMCDs (n=30) and practitioners (n=180) 
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In each team an Individual Team Manager, or a delegated senior practitioner, will be briefed by the research team about the
trial and provided with participant information sheets. Two practitioners in each team will be sought to act as volunteer
research coordinators and allowed up to three days from receiving the study information to decide if they wish to participate.
These staff will recruit the remaining practitioners from the team.
People with dementia and their carers (n=450)
People with dementia and their carers will be identi ed from new referrals to the team’s caseload. Team practitioners will
approach them and explain that their team is participating in the trial and that they are also invited to do so.
Consent process
During a site set-up visit to each TMCD the AQUEDUCT research team will take consent from the two TMCD practitioners
acting as research coordinators. These research coordinators will arrange and con rm consent with their fellow TMCD
practitioners, following the procedure used for con rmation of their own consent. This delegation of responsibility will be
recorded formally in the Site Delegation Log.
People with dementia and carers will be approached by TMCD practitioners and given an information sheet, opportunities to
ask questions and up to three days to decide if they wish to participate.  If they agree, formal consent will be obtained from
the person with dementia.  This consent will be seen as a continuing process and at each meeting the practitioner will
determine their capacity (according to the Mental Capacity Act 200524) to give informed consent to take part in the research.
A consent form will be completed separately with the carer regarding their involvement in the trial.
All participants will be informed of their right to withdraw from the research for any reason and at any time and that this
decision will not impact on their current or future work within clinical services or access to and use of services.     In certain
circumstances, the CI may withdraw people with dementia from the trial if it is no longer considered to be in their best interest
to continue. 
Outcome measures
The schedule of outcome measures and assessment points is provided in the SPIRIT chart (Figure 3).
Primary outcome measure
Psychiatric hospital admissions for people with dementia All psychiatric hospital admissions for people with dementia from
the TMCD catchment area (as de ned by post codes) will be collated and reported at baseline and six-month follow up point
for the preceding six-month period.
Secondary outcome measures for people with dementia
Acute/general hospital admissions for people with dementia All acute/general hospital admissions for people with dementia
from the TMCD catchment area (as de ned by post codes) will be collated and reported at baseline and six-month follow up
point for the preceding six-month period.
Secondary outcome measures for people with dementia and their carers
Service satisfaction (one measure) The Client Satisfaction Questionnaire (CSQ-8) is a brief satisfaction with service measure
and consists of eight items designed to measure satisfaction with health and human services in a single scale.25
Quality of life and psychological wellbeing (two measures) The EuroQol 5-dimension 5 level questionnaire (EQ-5D-5L) is a
brief assessment of quality of life which comprises  ve dimensions: mobility, self-care, usual activities, pain/discomfort and
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anxiety/depression each rated by  ve levels of severity.26,27 The General Health Questionnaire (GHQ-12) is a brief 12-item
scale which measures current mental health and psychological well-being.28
Secondary outcome measures for TMCD practitioners
Work environment (two measures) The Work Acceptance and Action Questionnaire (WAAQ) assesses psychological  exibility
in relation to the workplace and comprises seven items which rate ability or willingness to remain engaged in occupational
work while experiencing distressing thoughts and emotions.29 The Utrecht Work Engagement Scale (UWES) is a 17-item scale
measuring three dimensions of work engagement (vigour, dedication and absorption).30,31 
Wellbeing in Work (two measures) The General Health Questionnaire (GHQ-12) is a brief 12-item scale which measures
current mental health and psychological well-being.28 Sickness absence is used as a common proxy for work wellbeing and
will be collated for all TMCD practitioners for each team.  
Fidelity Measure (one measure) The Fidelity Measure is a measure of practice quality in managing crises and part of the
Resource Kit developed from the AQUEDUCT research programme. It will be completed by each TMCD in the intervention arm
only.
Cost measures
Resource use ( ve measures) Psychiatric hospital admissions for people with dementia within the TMCD’s catchment area
(as de ned by post codes) will be collated and reported at baseline and six month follow up point for the preceding six-month
period. Acute/general hospital admissions for people with dementia within the TMCD’s catchment area (as de ned by post
codes) will be collated and reported at baseline and six-month follow up point for the preceding six-month period. A record of
both the number of permanent care home admissions and respite care admissions from each TMCD during the intervention
phase will be collated to indicate use of other high-cost resources.  In the intervention arm only, staff time use in
implementing the Resource Kit and support time given to staff for this will capture additional costs of the intervention.   Cost
information will be collected using a ‘reduced list’ approach to costing32, re ecting the necessary parsimonious adaptation of
methodology required following the COVID-19 pandemic. This will avoid use of expensive-to-collect items of data which are
unlikely to vary and affect overall cost differences between the intervention arm and TAU arm, such as GP costs. 
Other data collected
Serious adverse events In accordance with Good Clinical Practice all data collectors will report deaths and adverse events
that are life threatening, require or extend hospitalisation, result in disability or incapacity or are otherwise signi cant. All
adverse events will be recorded in the case report form.
Procedure
Overall involvement in the trial will be for eight months, to include: provision of hospital admission data from all NHS Trusts
at baseline and six months follow up; initial set-up; completion of the Fidelity Measure before and after implementation of the
Resource Kit; and delivery of all participant-completed measures. TMCDs in the intervention arm will implement the Resource
Kit for six months and TMCDs in the control arm will deliver TAU for six months. 
Data collection
Data will be collected from NHS Trusts, TMCDs, team practitioners, and new referrals of people with dementia and carers to
these TMCDs.
Psychiatric hospital admissions data in the TMCD catchment area will be collated and reported by the relevant NHS Trust
Department retrospectively at baseline and at six-month follow up. Acute/general hospital admissions data from each TMCD
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catchment area will be collected from each hospital by the research team retrospectively at baseline and at six-month follow
up. Each TMCD in the intervention arm will complete the Resource Kit Fidelity Measure at baseline and six-month follow up to
identify gaps in their practice.
TMCD practitioners in both arms of the study will complete three questionnaires (WAAQ; UWES; GHQ-12) at baseline and at
six-month follow up point. Sickness absence will be collated at team level for all TMCD practitioners at baseline and at six-
month follow up point for the preceding six-month periods. In both study arms practitioners will record the number of
permanent care home admissions and respite care admissions throughout the intervention phase for those people with
whom the TMCD has engaged. TMCD practitioners in the intervention arm only will keep activity records to monitor time
spent implementing the Resource Kit during the research. 
After discharge from the TMCD service, people with dementia and carers will be asked to complete three questionnaires (CSQ-
8, EQ-5D-5L and GHQ-12). All measures can be completed within six weeks of discharge from the TMCD.
Random allocation
Following consent each TMCD will be entered onto a web-based randomisation system and be randomly assigned to one of
two arms, either using the Resource Kit or TAU with equal opportunity. The allocation will be determined by a computer
generated pseudo-random code using random permuted blocks of varying size, minimised by the number of people with
dementia admitted to psychiatric hospital in the previous six months (either classi ed as low if the number is less than 25, or
high if 25 or more) in each TMCD catchment area. The block size will not be disclosed to the research team. The
randomisation system was set up and managed by the Research and Innovation team at the University of Nottingham
(separate from the research team) in accordance with their standard operating procedure and is held on a secure server.  The
randomisation process is described in detail in a separate  le and held securely within the statistics master  le.
Masking
People with dementia, carers, statisticians, and the DMC will be blinded to TMCD arm allocation until the data analysis is
completed. However, masking of TMCDs is not possible.
Data management
Study data will be managed using REDCap electronic data capture tools (version 10.0.5 LTS)33,34 hosted at the University of
Nottingham.  All data will be treated in a con dential manner and in accordance with UK data protection legislation.  All
research staff and practitioners involved in the study will be appropriately trained and supported with regards to the
collection, storage, processing and disclosure of personal information. Unmasked researchers will enter data into REDCap
software in accordance with study speci c guidance. Each participant will be assigned a unique identi cation code that will
be used for all research data linkage and storage systems to ensure anonymity. Participants’ identi able information will be
stored securely, separate from the anonymised research data. A full audit trail will be maintained by recording all
amendments to data specifying reason and time.   Personal data will only be accessible to the minimum number of
individuals necessary for data analysis or audit. Data may be inspected and audited by the sponsor and research ethics
committee. Study investigators will have access to the study data by request from the CI and only anonymised data will be
transferred to co-investigators at other sites. Following completion of the study non-personal data will be stored for  ve years
in accordance with the terms of the Sponsor’s contract with the funder and personal data will be stored for three to six
months to allow completion of the research, and for results to be disseminated to participants if required.
Sample size
Information collected in different stages of the AQUEDUCT research programme, showed the average hospital admission
count per TMCD catchment area over a six-month period to be between 17 and 33.  Following stakeholder consultation, a 20
per cent reduction represented the minimum clinically signi cant difference in outcome. Therefore, 15 TMCDs will be required
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in each of the two study arms (30 in total) to detect a 7-point mean admission count difference between arms with 90 per
cent power at a two-tailed 0.05 signi cance level, assuming the count of hospital admissions follows a Poisson distribution.
Stata 16 software was used for this power analysis. It is anticipated that no TMCD will withdraw from the study and that
NHS Trusts will provide the required hospital admissions data for each TMCD; thus, the number of TMCDs required is unlikely
to be in uenced by lost information due to withdrawal.  However, to manage risk of loss, additional team sites will be kept in
reserve.
Statistical analysis
The data analysis will be conducted on an intention to treat basis. The treatment effects estimate (95% CI) on the primary
outcome and the number of general hospital admissions will be quanti ed using Poisson regression with binary arm status
as an exploratory variable and the size of the population with dementia within each TMCD catchment area as an offset. An
over-dispersion check will be performed, and a negative binomial regression model will be used if there is evidence that the
outcome variance is greater than the mean.  The treatment effect estimates on TMCD practitioners’ and people with dementia
and carers’ outcome measures will be explored using multilevel modelling with the TMCD as a level two analytical unit and
baseline measures included as covariates.35,36 Skewed continuous outcome variables will be transformed for multilevel
modelling, and nonlinear multilevel modelling will be performed for categorical outcomes. No interim analysis is planned, and
safety and adverse event information will be presented descriptively. Missing values will be imputed via analytical modelling
assuming missing at random status. Stata 17 will be used to analyse the data. 
Economic evaluation
A cost-consequences analysis will be undertaken, laying out a speci ed list of costs, including Resource Kit costs, service use
and trial outcomes (hospital admissions and quality of life measures). Bootstrapping will be used to generate incremental
cost-effectiveness ratios and plot cost-effectiveness acceptability curves. A cost-effectiveness analysis will be undertaken,
examining Resource Kit costs and secondary care use costs (using national unit cost measures) and comparing these with
changes in the primary outcome measure. Sensitivity analyses will be conducted to assess the implications of variations in
team staff case-mix upon outcomes.
The primary economic evaluation will be a cost-utility analysis from an NHS perspective based on the within-trial period. The
incremental cost per QALY (Quality-Adjusted Life Year) gained for the Resource Kit versus TAU will be calculated for the
average TMCD. QALYs gained will be estimated as the number of weeks multiplied by the utility of observed survival for
patients and carers within the average TMCD. The utility values will be estimated from the EQ-5D-5L health status
questionnaire27, completed at follow-up and the associated published societal utility tariffs.  
An economic analysis plan will be approved by the DMC before data are accessed. Statistical methods, such as accounting
for missing data and adjustment will be consistent with the statistical analysis plan.
Qualitative aspects of trial
To enhance understanding of participants’ experience of and engagement with the intervention the trial includes a qualitative
component.   Study-speci c questionnaires will be completed by 45 TMCD practitioners from the intervention arm of the trial
(three practitioners per team), and researchers will conduct semi-structured interviews remotely, via telephone or multimedia,
with 12 people with dementia or their carers who received input within the previous six weeks from a TMCD in the intervention
arm.
Both thematic and narrative analysis of interview transcripts will be deployed to identify experiences both of staff providing
the intervention and of people with dementia and their carers receiving it.  At least two researchers will review each transcript
to increase trustworthiness. Once all aspects are coded, key themes and processes will be identi ed through a process of
conceptual abstraction. The point of reaching thematic saturation37 will be agreed with members of the wider research team.
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Discussion
The AQUEDUCT programme is designed to address the better management of crises in the care of people with dementia.  The
trial is built upon knowledge gaps identi ed in previous work by team members16,19 and has involved literature reviews12, the
development of practice modules for service improvement,14,20  and a feasibility study.23
There is limited evidence for the precise content of crisis resolution services for people with dementia and their effectiveness
and cost-effectiveness. Nonetheless, people with dementia and carers value a coordinated and well-focused approach to
addressing crises in their care.15 Policy in dementia care continues to emphasise the importance of care at home and of
avoiding unnecessary admissions to hospital care.3,4,5,38 There is therefore a need for more precise evidence of the form and
content of an improved model of crisis services for people with dementia and their carers. 
Health and social care services need to better understand what interventions prevent hospitalisation and enhance well-being
for people with dementia and carers in the period leading up to or during a crisis.  This trial can contribute to such a
knowledge base if the intervention proves to be clinically and cost effective.  It is hypothesised that a more precise model of
crisis management, supported through provision of a Resource Kit, can reduce admissions to hospital and improve the well-
being of people with dementia and their carers.
This study could have wide-ranging value in improving crisis management for people with dementia and their carers and
evidencing what works for service commissioners and planners, health and social care professionals, and researchers both
nationally and internationally. Evidence from this study will be submitted for publication in peer-reviewed journals and
 ndings presented at relevant conferences and events. To achieve impact, the Resource Kit will be made available after the
trial has ended, as part of our programme of implementation and dissemination.
Trial status
 
The trial is due to commence recruitment in July 2021 and will continue until November 2022.
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Figure 3
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